DCISionRT by PreludeDx Identifies Women with DCIS with Unacceptably High Rates of Local Recurrence after Breast Conserving Surgery and Radiation Therapy
/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented data at the...
United States Dan Forche Andrew Wade Cory Dunn Frank Vicini Prnewswire Prelude Corporation Preludedx
Source: prnewswire.com